Literature DB >> 33553661

Long-term outcomes of perianal fistulizing Crohn's disease in the biologic era.

Tanya Lee1,2, Michael A Kamm1,2, Sally Bell1,2, Mark Lust1,2, Steve Brown1,2, Ola Niewiadomski1,2, Chamara Basnayake1,2, Emily Wright1,2, Basil D'Souza3, Rodney Woods3, Shu Chen Wei4, William Connell1,2, Alexander Thompson1,2, Eric Yong5, Nik Sheng Ding1,2.   

Abstract

BACKGROUND AND AIM: While the advent of biologic therapy has led to improved outcomes in perianal fistulizing Crohn's disease (pfCD), loss of response is common. Previous studies suggest that patients who achieve radiological healing (with healing of underlying tracts on magnetic resonance imaging [MRI]) have a longer duration of response. The aim of this study was to characterize MRI outcomes of pfCD at a specialist inflammatory bowel disease (IBD) unit and compare the long-term clinical outcomes between patients achieving MRI and clinical healing.
METHODS: A retrospective analysis of perianal fistulizing Crohn's patients treated at one specialist IBD unit was performed. Records were reviewed for patient demographics, disease history, clinical assessments, investigation results, and disease flares. Clinical remission was defined as closure of all baseline fistula openings. Radiological healing was defined as the absence of any T2-hyperintense sinuses, tracts, or collections. The primary end-point was rate of MRI healing. The secondary outcome was defined as flare-free period (time between clinical or radiological healing and patients' first signs/symptoms requiring therapy escalation).
RESULTS: A total of 93 patients were included, with a median follow-up of 4.8 years (interquartile range, 2.4-6 years). Of 44 patients, 22 (50%) achieved clinical remission, while 15 of 93 (16%) achieved radiological healing. Of 22 patients, 10 (45%) with clinical remission had a subsequent disease flare (median time of 7 months) compared with 3 of 15 (20%) patients with MRI healing (median time of 3.6 years). Radiological healing was associated with a significantly longer flare-free period (P = 0.01).
CONCLUSION: Radiological healing occurs less commonly but represents a deeper form of healing, associated with improved long-term clinical outcomes.
© 2020 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Crohn's disease; biological therapy; magnetic resonance imaging; perianal fistula; tumor necrosis factor‐alpha

Year:  2020        PMID: 33553661      PMCID: PMC7857282          DOI: 10.1002/jgh3.12475

Source DB:  PubMed          Journal:  JGH Open        ISSN: 2397-9070


  18 in total

1.  Infliximab for the treatment of fistulas in patients with Crohn's disease.

Authors:  D H Present; P Rutgeerts; S Targan; S B Hanauer; L Mayer; R A van Hogezand; D K Podolsky; B E Sands; T Braakman; K L DeWoody; T F Schaible; S J van Deventer
Journal:  N Engl J Med       Date:  1999-05-06       Impact factor: 91.245

2.  Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging.

Authors:  S J Bell; S Halligan; A C J Windsor; A B Williams; P Wiesel; M A Kamm
Journal:  Aliment Pharmacol Ther       Date:  2003-02       Impact factor: 8.171

Review 3.  AGA technical review on perianal Crohn's disease.

Authors:  William J Sandborn; Victor W Fazio; Brian G Feagan; Stephen B Hanauer
Journal:  Gastroenterology       Date:  2003-11       Impact factor: 22.682

4.  Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease.

Authors:  Gary R Lichtenstein; Songkai Yan; Mohan Bala; Marion Blank; Bruce E Sands
Journal:  Gastroenterology       Date:  2005-04       Impact factor: 22.682

5.  Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas.

Authors:  Siew C Ng; Sophie Plamondon; Arun Gupta; David Burling; Anna Swatton; Carolynne J Vaizey; Michael A Kamm
Journal:  Am J Gastroenterol       Date:  2009-09-15       Impact factor: 10.864

6.  Fistulizing perianal Crohn's disease: contrast-enhanced magnetic resonance imaging assessment at 1 year on maintenance anti-TNF-alpha therapy.

Authors:  C Savoye-Collet; G Savoye; E Koning; J N Dacher; E Lerebours
Journal:  Inflamm Bowel Dis       Date:  2010-11-29       Impact factor: 5.325

7.  Evaluation of an MRI-based score of disease activity in perianal fistulizing Crohn's disease.

Authors:  Karin Horsthuis; Manon L W Ziech; Shandra Bipat; Anje M Spijkerboer; Annette C de Bruine-Dobben; Daniel W Hommes; Jaap Stoker
Journal:  Clin Imaging       Date:  2011 Sep-Oct       Impact factor: 1.605

8.  Infliximab maintenance therapy for fistulizing Crohn's disease.

Authors:  Bruce E Sands; Frank H Anderson; Charles N Bernstein; William Y Chey; Brian G Feagan; Richard N Fedorak; Michael A Kamm; Joshua R Korzenik; Bret A Lashner; Jane E Onken; Daniel Rachmilewitz; Paul Rutgeerts; Gary Wild; Douglas C Wolf; Paul A Marsters; Suzanne B Travers; Marion A Blank; Sander J van Deventer
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

9.  Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn's disease.

Authors:  Lucie Thomassin; Laura Armengol-Debeir; Cloé Charpentier; Valerie Bridoux; Edith Koning; Guillaume Savoye; Céline Savoye-Collet
Journal:  World J Gastroenterol       Date:  2017-06-21       Impact factor: 5.742

Review 10.  Radiological outcomes in perianal fistulizing Crohn's disease: A systematic review and meta-analysis.

Authors:  Tanya Lee; Eric Yong; Nik S Ding
Journal:  JGH Open       Date:  2019-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.